-
Describe the design, patient population, primary outcome, and key findings of the CMR GUIDE randomized clinical trial.
-
Evaluate the limitations of using cardiovascular magnetic resonance–identified myocardial scar to guide primary prevention ICD implantation in patients with an LVEF of 36% to 50%.
-
Assess current challenges and emerging approaches to sudden cardiac death risk stratification, including the potential use of multimodal and dynamic risk-prediction models.
Host: Jason T. Jacobson, MD, FHRS
Guests: Sei Iwai, MD, FHRS and Jeanne E. Poole, MD, FHRS, CCDS
Faculty Disclosures:
J. Jacobson
-
Honoraria/Speaking/Consulting Fee: Zoll Medical Corporation, Vektor Medical, Inc., CardioFocus, Inc., Abbott Medical, Johnson and Johnson
-
Stock Options-Privately Held: Atlas 5D
S. Iwai
- Honoraria/Speaking/Consulting Fee: Alta Thera Pharmaceuticals, Biotronik, Johnson and Johnson, CardioFocus, Inc.
J. Poole
-
Honoraria/Speaking/Consulting Fee: Heart Rhythm Society
-
Research (Contracted Grants): Boston Scientific, AtriCure, Inc., Kestra, Inc., Biotronik